AV000103A (ICVAX) vs BNT168
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV antigens · full HIV pipeline
AV000103A (ICVAX)
Developed by Immuno Cure BioTech
NCT06253533 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Incidence of adverse events at week 36 [Safety and Tolerability]". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: March 2027 · NCT07530198 (registry estimate)
Reported efficacy
Incidence of adverse events at week 36 [Safety and Tolerability]: All 45 participants, randomised across 1 mg, 2 mg and 4 mg dosing groups at an ICVAX to placebo ratio of 12:3, completed the scheduled visits. All reported treatment-related adverse events were mild and no treatment-related severe adverse events occurred. Among those receiving the optimal dose, a large majority had a more than 2-fold increase in T cell responses.
Result source: NCT06253533
BNT168
Developed by BioNTech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2028 · NCT07698600 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AV000103A (ICVAX) | BNT168 |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not reported |
| CD4 count, change (week 48) | —Not reported | —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- AV000103A (ICVAX)
- —Not reported
- BNT168
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- AV000103A (ICVAX)
- —Not reported
- BNT168
- —Not reported
CD4 count, change (week 48)
- AV000103A (ICVAX)
- —Not reported
- BNT168
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AV000103A (ICVAX): no structured comparison results are available for HIV.
BNT168: no structured comparison results are available for HIV.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AV000103A (ICVAX)'s landscape · BNT168's landscape